切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2024, Vol. 13 ›› Issue (03) : 363 -369. doi: 10.3877/cma.j.issn.2095-3232.2024.03.018

基础研究

CDC42EP2基因与肝癌预后、免疫细胞浸润关系及其对细胞迁移侵袭的影响
曾谣1, 谢琴2, 陈显育3, 王平根2, 毛玲秋2, 何丹玲2, 杜飞2, 郑希彦2, 何函樨2,†()   
  1. 1. 518000　深圳，中山大学附属第八医院运动医学科
    2. 518000　深圳，中山大学附属第八医院肝胆胰外科
    3. 510630　广州，中山大学附属第三医院肝胆外科
  • 收稿日期:2024-02-25 出版日期:2024-06-10
  • 通信作者: 何函樨
  • 基金资助:
    深圳市科技创新委基础研究面上项目(JCYJ20220530144404011)

Relationship between CDC42EP2 gene and prognosis of hepatocellular carcinoma, immune cell infiltration and its effects on cell migration and invasion

Yao Zeng1, Qin Xie2, Xianyu Chen3, Pinggen Wang2, Lingqiu Mao2, Danling He2, Fei Du2, Xiyan Zheng2, Hanxi He2,†()   

  1. 1. Department of Sports Medicine, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518000, China
    2. Department of Hepatobiliary and Pancreatic Surgery, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518000, China
    3. Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2024-02-25 Published:2024-06-10
  • Corresponding author: Hanxi He
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

曾谣, 谢琴, 陈显育, 王平根, 毛玲秋, 何丹玲, 杜飞, 郑希彦, 何函樨. CDC42EP2基因与肝癌预后、免疫细胞浸润关系及其对细胞迁移侵袭的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 363-369.

Yao Zeng, Qin Xie, Xianyu Chen, Pinggen Wang, Lingqiu Mao, Danling He, Fei Du, Xiyan Zheng, Hanxi He. Relationship between CDC42EP2 gene and prognosis of hepatocellular carcinoma, immune cell infiltration and its effects on cell migration and invasion[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 363-369.

目的

探讨CDC42EP2基因与肝细胞癌（肝癌）患者预后和免疫细胞浸润的关系及其对细胞迁移侵袭的影响。

方法

从癌症基因组图谱（TCGA）数据库下载肝癌组织与正常肝组织中CDC42EP2基因表达谱数据，分析肝癌组织CDC42EP2基因表达与临床病理特征的相关性，并用Kaplan-Meier Plotter数据库进行生存预后分析；利用HCCDB数据库分析CDC42EP2的共表达网络；利用TIMER2.0数据库探讨CDC42EP2表达与免疫细胞浸润的相关性；采用siRNA技术抑制HepG2肝癌细胞中CDC42EP2基因表达，qRT-PCR及Transwell实验分别检测CDC42EP2对肝癌细胞迁移和侵袭能力的影响。

结果

TCGA数据库分析显示，肝癌组织CDC42EP2表达明显高于正常肝组织（P<0.05），肝癌组织CDC42EP2表达与肝癌病理组织学分级、TNM分期、TP53突变相关（P<0.05）。肝癌组织CDC42EP2高表达患者中位生存时间为41.0个月，明显低于低表达患者的84.4个月（HR=1.86，P<0.05）。CDC42EP2表达与辅助性T细胞（Th）、中央记忆型T细胞（Tcm）及Th2细胞浸润成正比，而与树突状细胞（DC）及Th17细胞浸润成反比（r=0.179，0.172，0.144，-0.125，-0.182；P<0.05）。siRNA敲低CDC42EP2基因后，HepG2肝癌细胞迁移和侵袭能力显著降低。

结论

肝癌组织CDC42EP2基因高表达，其高表达与肝癌预后不良有关。敲低CDC42EP2基因可抑制肝癌细胞的迁移和侵袭能力。

关键词: 癌，肝细胞, 细胞分裂周期蛋白42（CDC42）, CDC42效应蛋白2, 预后, 免疫浸润, 侵袭
Objective

To investigate the relationship between CDC42EP2 gene and prognosis, immune cell infiltration in patients with hepatocellular carcinoma (HCC) and its effects on cell migration and invasion.

Methods

The expression profile data of CDC42EP2 gene in HCC and normal liver tissues were downloaded from The Cancer Genome Atlas (TCGA) database. The correlation between CDC42EP2 gene expression in HCC tissues and clinicopathological characteristics was analyzed. Survival analysis was performed by Kaplan-Meier Plotter. The co-expression network of CDC42EP2 was determined by using HCCDB database. The correlation between CDC42EP2 expression and immune cell infiltration was evaluated by using TIMER2.0 database. The expression of CDC42EP2 gene in HepG2 cells was suppressed by siRNA technology. The effects of CDC42EP2 on cell migration and invasion were assessed byqRT-PCR and Transwell chamber assay.

Results

TCGA database analysis showed that the expression level of CDC42EP2 in HCC tissues was significantly higher than that in normal liver tissues (P<0.05). Expression of CDC42EP2 in HCC tissues was correlated with histopathological grade, TNM stage and TP53 mutation (P<0.05). The median survival of patients with high expression of CDC42EP2 in HCC tissues was 41.0 months, significantly shorter than 84.4 months of those with low CDC42EP2 expression (HR=1.86, P<0.05). The expression level of CDC42EP2 was positively associated with the infiltration of helperT cells (Th), central memory T cells (Tcm) and Th2 cells, but negatively associated with the infiltration of dendritic cells (DC) and Th17 cells (r=0.179, 0.172, 0.144, -0.125, -0.182; P<0.05). After CDC42EP2 gene was knockdowned by siRNA technology, the migration and invasion capabilities of HepG2 cells were significantly weakened.

Conclusions

CDC42EP2 gene is highly expressed in HCC, which is correlated with poor prognosis of HCC patients. Knockdown of CDC42EP2 gene can inhibit the migration and invasion of HCC cells.

Key words: Carcinoma, hepatocellular, Cell division cycle 42 (CDC42), CDC42 effector protein 42, Prognosis, Immune infiltration, Invasion
图1 TCGA数据库肝癌组织中CDC42EP2的表达注：a为TCGA数据库示肝癌组织中CDC42EP2 mRNA高表达；b为免疫组化法检测示肝癌组织CDC42EP2蛋白高表达；CDC42EP2为细胞分裂周期42效应因子蛋白2，TCGA为癌症基因组图谱，***为P<0.001
图2 TCGA数据库中CDC42EP2表达与肝癌患者临床病理特征的关系注：a、b、c分别示CDC42EP2 mRNA表达与肝癌病理组织学分级、TNM分期和TP53突变相关；CDC42EP2为细胞分裂周期42效应因子蛋白2，*为P<0.05，**为P<0.01
图3 TCGA数据库中CDC42EP2 mRNA表达水平与肝癌患者预后的关系注：CDC42EP2高表达与肝癌患者预后不良相关；CDC42EP2为细胞分裂周期42效应因子蛋白2，TCGA为癌症基因组图谱
图4 CDC42EP2在肝癌组织的共表达分析及免疫细胞浸润的相关性注：a为HCCDB数据库分析CDC42EP2的共表达网络，b为棒棒图示肝癌组织中CDC42EP2表达与肿瘤免疫细胞浸润的相关性；CDC42EP2为细胞分裂周期42效应因子蛋白2，Th为辅助性T细胞，Tcm为中央记忆型T细胞，Tem为效应记忆T细胞，Tgd为γδT细胞，TFH为滤泡辅助T细胞，TReg为调节性T细胞，DC为树突状细胞，aDC、iDC、pDC分别为活化的树突状细胞、间质性树突状细胞、浆细胞样树突状细胞
图5 敲低CDC42EP2显著抑制肝癌HepG2细胞迁移及侵袭能力注：a为qRT-PCR检测LO2、Hep3B、HepG2及Huh7细胞系中CDC42EP2 mRNA表达量；b为qRT-PCR检测HepG2细胞系转染siCDC42EP2后CDC42EP2 mRNA表达量变化；c为Transwell实验检测HepG2细胞转染siCDC42EP2后迁移及侵袭的变化；**为P<0.01，ns为差异无统计学意义
[1]
Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360):1345-1362.
[2]
Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
[3]
Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2):477-491, e1.
[4]
Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1-61.
[5]
Wu M, Yang G, Chen Y, et al. CEP2 attenuates myoblast differentiation but does not affect proliferation[J]. Int J Biol Sci, 2015, 11(1):99-108.
[6]
Bryan BA, Li D, Wu X, et al. The Rho family of small GTPases: crucial regulators of skeletal myogenesis[J]. Cell Mol Life Sci, 2005, 62(14):1547-1555.
[7]
Wang T, Rao D, Yu C, et al. RHO GTPase family in hepatocellular carcinoma[J]. Exp Hematol Oncol, 2022, 11(1):91.
[8]
Chan W, Kozma R, Yasui Y, et al. Vimentin intermediate filament reorganization by Cdc42: involvement of PAK and p70 S6 kinase[J]. Eur J Cell Biol, 2002, 81(12):692-701.
[9]
Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis[J]. Br J Pharmacol, 2014, 171(24):5507-5523.
[10]
Liu D, Song T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China[J]. Biosci Trends, 2021, 15(3):142-147.
[11]
Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments[J]. Clin Liver Dis, 2023, 27(1):85-102.
[12]
Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma[J]. Genes Dis, 2020, 7(3):308-319.
[13]
张超，陈卓妙语，程倩, 等. ARID1A在肝内胆管癌患者中的表达及与肿瘤微环境的关系[J]. 中华普通外科杂志, 2023, 38(5):362-366.
[14]
Di Ciano-Oliveira C, Thirone ACP, Szászi K, et al. Osmotic stress and the cytoskeleton: the R(h)ole of Rho GTPases[J]. Acta Physiol, 2006, 187(1/2):257-272.
[15]
Hirsch DS, Pirone DM, Burbelo PD. A new family of Cdc42 effector proteins, CEPs, function in fibroblast and epithelial cell shape changes[J]. J Biol Chem, 2001, 276(2):875-883.
[16]
Calvo F, Ranftl R, Hooper S, et al. Cdc42EP3/BORG2 and septin network enables mechano-transduction and the emergence of cancer-associated fibroblasts[J]. Cell Rep, 2015, 13(12):2699-2714.
[17]
Ageta-Ishihara N, Yamazaki M, Konno K, et al. A CDC42EP4/septin-based perisynaptic glial scaffold facilitates glutamate clearance[J]. Nat Commun, 2015, 6: 10090.
[18]
Farrugia AJ, Rodríguez J, Orgaz JL, et al. CDC42EP5/BORG3 modulates SEPT9 to promote actomyosin function, migration, and invasion[J]. J Cell Biol, 2020, 219(9):e201912159.
[19]
Joberty G, Perlungher RR, Macara IG. The Borgs, a new family of Cdc42 and TC10 GTPase-interacting proteins[J]. Mol Cell Biol, 1999, 19(10):6585-6597.
[20]
Burbelo PD, Snow DM, Bahou W, et al. MSE55, a Cdc42 effector protein, induces long cellular extensions in fibroblasts[J]. Proc Natl Acad Sci U S A, 1999, 96(16):9083-9088.
[21]
Farrugia AJ, Calvo F. Cdc42 regulates Cdc42EP3 function in cancer-associated fibroblasts[J]. Small GTPases, 2017, 8(1):49-57.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[8] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[9] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[10] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[11] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[12] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[13] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？